Ra ( = 3.63 d), an α-emitting radionuclide, holds significant promise in cancer endoradiotherapy. Current Ra-related therapy is still scarce because of the lack of reliable radionuclide supply. The Th-Ra radionuclide generator can undoubtedly introduce continuous and sustainable availability of Ra for advanced nuclear medicine. However, conventional metal oxides for such radionuclide generators manifest suboptimal adsorption capacities for the parent nuclide, primarily attributable to their limited surface area. In this work, core-shell SiO@TiO microspheres were proposed to develop as column materials for the construction of a Th-Ra generator. SiO@TiO microspheres were well prepared and systematically characterized, which has also been demonstrated to have good adsorption capacity to Th and very weak binding affinity toward Ra via simulated chemical separation. Upon introducing Th-containing solution onto the SiO@TiO functional column, a Th-Ra generator with excellent retention of the parent radionuclide and ideal elution efficiency of daughter radionuclide was obtained. The prepared Th-Ra generator can produce Ra with high purity and medical usability in good elution efficiency (98.72%) even over five cycles. To the best of our knowledge, this is the first time that the core-shell mesoporous materials have been applied in a radionuclide generator, which can offer valuable insights for materials chemistry, radiochemical separation, and biological medicine.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1021/acs.langmuir.4c01138 | DOI Listing |
EJNMMI Radiopharm Chem
November 2024
Department of Nuclear Medicine, University Hospital Carl Gustav Carus, Technical University Dresden, Fetscherstr. 74, 01307, Dresden, Germany.
Background: Recently, radiotheranostics comprising the true matched radionuclide pair Pb could serve as real dosimetric planning utility using Pb-radiolabelled pharmaceuticals before therapy with Pb-radiolabelled counterparts. Pb might act as the missing radionuclide therapy between standard β therapies (e.g.
View Article and Find Full Text PDFBackground: Bi is a short-lived radionuclide currently trialed for alpha therapy of various oncological diseases. A serious obstacle to the wide medical use is decay losses of Bi during a conventional synthesis of radiopharmaceuticals. In this work, we aimed to develop a two-column Aс/Bi generator providing the accumulation of Bi separately from the parent Ac via continuous circular separation and decay of intermediate Fr.
View Article and Find Full Text PDFAppl Radiat Isot
January 2025
Institute for Nuclear Research of Russian Academy of Sciences, Moscow, Troitsk, 117312, Russia.
The article presents a novel gas-chemical approach for Ac/Bi generators, which provides effective separation of Bi from parent Ac. The main problem with the generators of high activity is the radiation stability of sorbents, which is not substantial in this gas-chemical method of separation, where only radiationally stable inorganic materials are used. The approach includes heating at high temperature (about 900-1000 °C) Ac sample deposited on a backing material (Nb, quartz glass, stainless steel) in hydrogen-containing inert gas flow.
View Article and Find Full Text PDFRSC Adv
October 2024
Belgian Nuclear Research Centre (SCK CEN), Institute for Nuclear Materials Science Boeretang 200 B-2400 Mol Belgium.
Theranostics
October 2024
Department of Nuclear Medicine, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China.
Pb, a promising alphaparticle generator of Bi, has aroused much interest as a therapeutic radionuclide. For the development of targeted alpha therapy (TAT), it is important to determine the contribution of targeted effects in irradiated cells, and also of non-targeted effects in non-irradiated bystander cells. Currently, the critical roles of mitochondrial transfer in cellular crosstalk have garnered significant attention.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!